文献速递脑血管病神经重症与神经感染

急性缺血性卒中血管内取栓后出血转化的临床与影像学指标

Clinical and Imaging Indicators of Hemorrhagic Transformation in Acute Ischemic Stroke After Endovascular Thrombectomy.
PubMed 文献 · Stroke · 2021-12-07

DIRECT-MT 随机试验纳入 633 例急性缺血性卒中血管内取栓患者,分析出血转化、症状性颅内出血和脑实质血肿的临床与影像学预测因素。结果显示症状性颅内出血与基线 NIHSS 评分和入院血糖相关,阿替普酶治疗未增加出血转化、症状性颅内出血或脑实质血肿风险。

要点

  • 症状性颅内出血与较高基线 NIHSS 评分和入院血糖水平相关。
  • 阿替普酶治疗未增加取栓后出血转化、症状性颅内出血或脑实质血肿风险。
  • 单纯取栓组与联合治疗组的症状性颅内出血独立预测因素不同。

核心结论

  • 在 DIRECT-MT 试验中,症状性颅内出血的独立预测因素为基线 NIHSS 评分和入院血糖水平。
  • 阿替普酶治疗未增加血管内取栓后出血转化、症状性颅内出血或脑实质血肿的风险。
  • 单纯取栓组与联合治疗组的症状性颅内出血独立预测因素不同。

研究设计与样本

  • DIRECT-MT 为多中心随机临床试验,比较单纯血管内取栓与静脉溶栓联合血管内取栓。
  • 共分析 633 例患者,其中 320 例在联合治疗组。
  • 出血转化、症状性颅内出血和脑实质血肿通过随访计算机断层扫描评估。
  • 采用多变量序贯逻辑回归分析逐步选定的决定因素与出血转化、症状性颅内出血和脑实质血肿的关联。

主要发现

  • 633 例患者中,261 例(41.2%)发生出血转化,34 例(5.4%)发生症状性颅内出血,85 例(13.4%)发生脑实质血肿。
  • 中位年龄 69 岁,男性占 56.7%,中位 NIHSS 评分为 18。
  • 症状性颅内出血与较高基线 NIHSS 评分相关(校正比值比[OR],1.06[95%CI,1.10-1.12])及较高入院血糖水平相关(校正OR,1.14[95%CI,1.00-1.29])。
  • 阿替普酶治疗与出血转化、症状性颅内出血或脑实质血肿之间未发现关联。
  • 单纯取栓组中症状性颅内出血的独立预测因素为较高基线 NIHSS 评分(校正OR,1.09[95%CI,1.01-1.18])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prior studies have investigated the clinical and imaging factors for hemorrhagic transformation (HT), especially symptomatic intracranial hemorrhage (sICH); however, whether alteplase increases the risk of HT after endovascular thrombectomy (EVT) is unknown. This study aimed to assess clinical and imaging features associated with HT, sICH, and parenchymal hematoma (PH) in patients with acute ischemic stroke after EVT, with and without intravenous alteplase in DIRECT-MT (Direct Intraarterial Thrombectomy to Revascularize Acute Ischemic Stroke Patients with Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals: a Multicenter Randomized Clinical Trial). METHODS: The DIRECT-MT trial is a randomized trial of EVT alone versus intravenous thrombolysis combined with EVT. HT, sICH, and PH was evaluated on follow-up computed tomography. Multivariable ordinal logistic regression analysis was used to test the association of stepwise selected determinants with HT, sICH, and PH. RESULTS: In total, 633 patients were analyzed; 261 (41.2%) had HT; 34 (5.4%) had sICH; and 85 (13.4%) had PH. The median age was 69, and 56.7% were men. The median National Institutes of Health Stroke Scale score was 18, and 320 patients were in combination-therapy group. Symptomatic intracranial hemorrhage was associated with higher baseline National Institutes of Health Stroke Scale score (adjusted odds ratio [OR], 1.06 [95% CI, 1.10-1.12]) and higher glucose level at hospital arrival (adjusted OR, 1.14 [95% CI, 1.00-1.29]). No association was found between alteplase treatment and HT, sICH, or PH. The independent predictor of sICH was higher baseline National Institutes of Health Stroke Scale score (adjusted OR, 1.09 [95% CI, 1.01-1.18]) in EVT alone group, and history of anticoagulant drugs (adjusted OR, 3.75 [95% CI, 1.07-13.06]), higher glucose level at hospital arrival (adjusted OR, 1.19 [95% CI, 1.03-1.38]), >3 passes of device (adjusted OR, 4.42 [95% CI, 1.36-14.32]) in combination-therapy group. CONCLUSIONS: In DIRECT-MT, independent predictors of sICH were baseline National Institutes of Health Stroke Scale score and glucose level at hospital arrival. Alteplase treatment did not increase the risk of HT, sICH, or PH after EVT. The independent predictor of sICH was different in EVT alone group and combination-therapy group. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03469206.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Tian B, Tian X, Shi Z, et al. Clinical and Imaging Indicators of Hemorrhagic Transformation in Acute Ischemic Stroke After Endovascular Thrombectomy. Stroke. 2021. PMID: 34872341. doi:10.1161/STROKEAHA.121.035425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。